Literature DB >> 2054319

Dose-limiting hypotension with the 5-HT3-antagonist batanopride (BMY-25801).

J Herrstedt1, B H Jeppesen, P Dombernowsky.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2054319     DOI: 10.1093/oxfordjournals.annonc.a057882

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

Review 1.  5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis.

Authors:  M S Aapro
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

2.  The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment.

Authors:  J V St Peter; M E Brady; E F Foote; K A Dandekar; L Smaldone; J L Pykkonen; W F Keane; C E Halstenson
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 3.  Future of the management of emesis.

Authors:  S M Grunberg
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.